These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33242285)

  • 1. Persistent Tinnitus after Inhaled N,N-dimethyltryptamine (DMT).
    Diab H; Malcolm B
    J Psychoactive Drugs; 2021; 53(2):140-145. PubMed ID: 33242285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives.
    Kaypak AC; Raz A
    Transcult Psychiatry; 2022 Oct; 59(5):665-674. PubMed ID: 36031848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of classic psychedelics among adults: a Danish online survey study.
    Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
    Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.
    Winstock AR; Kaar S; Borschmann R
    J Psychopharmacol; 2014 Jan; 28(1):49-54. PubMed ID: 24284475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
    Cameron LP; Olson DE
    ACS Chem Neurosci; 2018 Oct; 9(10):2344-2357. PubMed ID: 30036036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS; Parker SE; Weleff J
    Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying.
    Sweeney MM; Nayak S; Hurwitz ES; Mitchell LN; Swift TC; Griffiths RR
    PLoS One; 2022; 17(8):e0271926. PubMed ID: 36001643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
    Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
    J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing Psychedelics and MDMA.
    Liechti ME; Holze F
    Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review.
    Więckiewicz G; Stokłosa I; Piegza M; Gorczyca P; Pudlo R
    Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelic microdosing benefits and challenges: an empirical codebook.
    Anderson T; Petranker R; Christopher A; Rosenbaum D; Weissman C; Dinh-Williams LA; Hui K; Hapke E
    Harm Reduct J; 2019 Jul; 16(1):43. PubMed ID: 31288862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the Top-Cited Articles on Classic Psychedelics.
    Lawrence DW; Sharma B; Griffiths RR; Carhart-Harris R
    J Psychoactive Drugs; 2021; 53(4):283-298. PubMed ID: 33535907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sociological investigations of human enhancement drugs: The case of microdosing psychedelics.
    Liokaftos D
    Int J Drug Policy; 2021 Sep; 95():103099. PubMed ID: 33518382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.